Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Jaeger

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Journal of Oncology|March 13, 2010
Advanced malignant melanoma: immunologic and multimodal therapeutic strategiesNiels Halama, Inka Zoernig, Dirk Jaeger
Expert Review of Anticancer Therapy|October 24, 2018
Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectivesCarlo Fremd, Dirk Jaeger, Andreas Schneeweiss
Seminars in Cancer Biology|March 5, 2018
Genomics and emerging biomarkers for immunotherapy of colorectal cancerJakob Nikolas Kather, Niels Halama, Dirk Jaeger
Tumori|July 31, 2014
Efficacy and safety of trastuzumab-based therapy in combination with different chemotherapeutic regimens in advanced esophagogastric cancer--a single cancer-center experienceGeorg-Martin Haag, Leonidas Apostolidis, Dirk Jaeger
Journal of Oncology|August 31, 2011
Targeting the tumor microenvironment: focus on angiogenesisFengjuan Fan, Alexander Schimming, Dirk Jaeger, et al.
Anticancer Research|February 6, 2009
Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancerNiels Halama, Christina Herrmann, Dirk Jaeger, et al.
Oncoimmunology|June 22, 2012
The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way aheadNiels Halama, Inka Zoernig, Niels Grabe, et al.
Expert Opinion on Pharmacotherapy|February 14, 2012
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesSonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, et al.
Medicine|July 22, 2016
Exercise and cancer: return to work as a firefighter with ostomy after rectal carcinoma - a case reportJoachim Wiskemann, Kai Schommer, Dirk Jaeger, et al.
Oncology|May 24, 2008
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancerChristina Herrmann, Ulrich Abel, Wolfgang Stremmel, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Journal of Oncology|March 13, 2010
Advanced malignant melanoma: immunologic and multimodal therapeutic strategiesNiels Halama, Inka Zoernig, Dirk Jaeger
Expert Review of Anticancer Therapy|October 24, 2018
Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectivesCarlo Fremd, Dirk Jaeger, Andreas Schneeweiss
Seminars in Cancer Biology|March 5, 2018
Genomics and emerging biomarkers for immunotherapy of colorectal cancerJakob Nikolas Kather, Niels Halama, Dirk Jaeger
Tumori|July 31, 2014
Efficacy and safety of trastuzumab-based therapy in combination with different chemotherapeutic regimens in advanced esophagogastric cancer--a single cancer-center experienceGeorg-Martin Haag, Leonidas Apostolidis, Dirk Jaeger
Journal of Oncology|August 31, 2011
Targeting the tumor microenvironment: focus on angiogenesisFengjuan Fan, Alexander Schimming, Dirk Jaeger, et al.
Anticancer Research|February 6, 2009
Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancerNiels Halama, Christina Herrmann, Dirk Jaeger, et al.
Oncoimmunology|June 22, 2012
The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way aheadNiels Halama, Inka Zoernig, Niels Grabe, et al.
Expert Opinion on Pharmacotherapy|February 14, 2012
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesSonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, et al.
Medicine|July 22, 2016
Exercise and cancer: return to work as a firefighter with ostomy after rectal carcinoma - a case reportJoachim Wiskemann, Kai Schommer, Dirk Jaeger, et al.
Oncology|May 24, 2008
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancerChristina Herrmann, Ulrich Abel, Wolfgang Stremmel, et al.
Pageof 6